Abstract
Alzheimers disease is characterized by the extracellular deposition of the amyloid β-peptide that derives from its precursor bAPP by sequential actions of β- and γ- secretases, respectively. Recent studies aimed at identifying these enzymes have been reported as it is thougth that their inhibition should hopefully lead to reduce Aβ load in the AD brains. β-secretase seems to be due to BACE1, a novel membrane-bound aspartyl protease. γ-secretase identification is still a matter of controversy. Invalidation of presenilin genes was reported to impair both γ-secretase-mediated Aβ production and Notch cleavage leading to NICD production. This observation together with another biochemical and pharmacological evidences led to suggest that presenilins could be the genuine long-searched γ-secretase that would be responsible for both APP and Notch cleavages. We have designed novel non peptidic potential inhibitors of g-secretase (referred to as JLK inhibitors) and examined their ability to prevent Aβ40 and Aβ42 secretions as well as NICD production. Three out of a series of these agents drastically lower the recoveries of both Aβ40 and Aβ42 produced by bAPP-expressing cell lines and concomitantly protect intracellular C99 and C83 recoveries. These inhibitors also prevent Aβ40/42 productions by C99-expressing cells. Interestingly, these inhibitors were totally unable to affect the DENotch cleavage leading to NICD generation. Here, we also further characterize the pharmacological properties and specificity of these JLK inhibitors.
Keywords: amyloidogenic cascade, neurodegeneration, Notch cleavage, c-cadherins, fluorimetric assays, gsk inhibitor
Current Alzheimer Research
Title: JLK Inhibitors: Isocoumarin Compounds as Putative Probes to Selectively Target the γ-Secretase Pathway
Volume: 2 Issue: 3
Author(s): Checler Frederic, Alves da Costa Cristine, Ayral Erwan, Andrau David, Dumanchin Cecile, Farzan Michael, Hernandez Jean-Francois, J. Martinez, Lefranc-Jullien Solveig, Marambaud Philippe, Pasini Andrea, Petit Agnes, Phiel Christopher, Robert Philippe, St George-Hyslop Peter and Wilk Sherwin
Affiliation:
Keywords: amyloidogenic cascade, neurodegeneration, Notch cleavage, c-cadherins, fluorimetric assays, gsk inhibitor
Abstract: Alzheimers disease is characterized by the extracellular deposition of the amyloid β-peptide that derives from its precursor bAPP by sequential actions of β- and γ- secretases, respectively. Recent studies aimed at identifying these enzymes have been reported as it is thougth that their inhibition should hopefully lead to reduce Aβ load in the AD brains. β-secretase seems to be due to BACE1, a novel membrane-bound aspartyl protease. γ-secretase identification is still a matter of controversy. Invalidation of presenilin genes was reported to impair both γ-secretase-mediated Aβ production and Notch cleavage leading to NICD production. This observation together with another biochemical and pharmacological evidences led to suggest that presenilins could be the genuine long-searched γ-secretase that would be responsible for both APP and Notch cleavages. We have designed novel non peptidic potential inhibitors of g-secretase (referred to as JLK inhibitors) and examined their ability to prevent Aβ40 and Aβ42 secretions as well as NICD production. Three out of a series of these agents drastically lower the recoveries of both Aβ40 and Aβ42 produced by bAPP-expressing cell lines and concomitantly protect intracellular C99 and C83 recoveries. These inhibitors also prevent Aβ40/42 productions by C99-expressing cells. Interestingly, these inhibitors were totally unable to affect the DENotch cleavage leading to NICD generation. Here, we also further characterize the pharmacological properties and specificity of these JLK inhibitors.
Export Options
About this article
Cite this article as:
Frederic Checler, Cristine da Costa Alves, Erwan Ayral, David Andrau, Cecile Dumanchin, Michael Farzan, Jean-Francois Hernandez, Martinez J., Solveig Lefranc-Jullien, Philippe Marambaud, Andrea Pasini, Agnes Petit, Christopher Phiel, Philippe Robert, St George-Hyslop Peter and Sherwin Wilk, JLK Inhibitors: Isocoumarin Compounds as Putative Probes to Selectively Target the γ-Secretase Pathway, Current Alzheimer Research 2005; 2 (3) . https://dx.doi.org/10.2174/1567205054367874
DOI https://dx.doi.org/10.2174/1567205054367874 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Current Medicinal Chemistry Mechanisms of Colon Cancer Prevention with and Beyond COX-2 Inhibition
Current Topics in Medicinal Chemistry Epidemics and Peptide Vaccine Response: A Brief Review
Current Topics in Medicinal Chemistry The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets The Clinical Perspective on Value of 3D, Thin Slice T2-Weighted Images in 3T Pelvic MRI for Tumors
Current Medical Imaging Anti-Tumor Mechanisms of Novel 3-(4-Substituted Benzyl)-5-Isopropil-5- Phenylhydantoin Derivatives in Human Colon Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Wet-lab Tested MicroRNA Assays for qPCR Studies with SYBR<sup>®</sup> Green and DNA Primers in Pig Tissues
MicroRNA Targeted Delivery of Bleomycin: A Comprehensive Anticancer Review
Current Cancer Drug Targets Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Diabetes Case Identification Methods Applied to Electronic Medical Record Systems: Their Use in HIV-Infected Patients
Current HIV Research Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Current Pharmaceutical Design The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry Investigation of Methylene Blue Release from Functional Polymeric Systems Using Dielectric Analysis
Current Drug Delivery The Protein-Protein Interaction-Mediated Inactivation of PTEN
Current Molecular Medicine Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Current Pharmaceutical Design Bone: A Fertile Soil for Cancer Metastasis
Current Drug Targets The Significance of Ubiquitin Proteasome Pathway in Cancer Development
Recent Patents on Anti-Cancer Drug Discovery Design, Synthesis and Evaluation of Peroxisome Proliferator-Activated Receptor α/βDual Agonists for the Treatment of Type 2 Diabetes
Letters in Drug Design & Discovery PPARδ Signaling Regulates Colorectal Cancer
Current Pharmaceutical Design Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations
Current Drug Metabolism